Cite

    C. Moussa et al.. “A novel small molecule tyrosine kinase inhibitor (GUtinib) preferentially targets discoidin domain receptors and reduces toxic proteins in neurodegeneration.” Parkinsonism & related disorders, vol. 79, n.d., pp. e67–. http://access.bl.uk/ark:/81055/vdc_100118540368.0x00001b